By Attending This Course, You WillBe able to manage medical affairs not only from a scientific perspective but also from the perspective of a brand’s commercial success factors.Learn how medical affairs can contribute to market understanding and to brand development strategy.Be equipped with the insights and tools to develop a competitive medical affairs strategy and to decide on the optimal tactical mix.Learn the pros and cons of commonly used medical affairs tactics.Develop a medical affairs perspective on pharmacoeconomics and market access.Benefit from Chris' wealth of experience in working with medical affairs departments across a wide spectrum of therapeutic and geographical markets.Why You Should AttendIn the past, pharma companies were largely fuelled by their own R&D departments developing small-molecule solutions to large patient populations. In that era, sales and marketing took the lead and scientific concerns were very much secondary to promotion.  Medical affairs departments were often a back-office service that made sure the marketing heroes did not let their exuberance for the brand take them too far. The Content: Modern Pharma is now facing a new multi-stakeholder and digitalised environment governed by market access hurdles, where the word value influences everything we do. In this new environment, medical affairs departments play a critical role in paving the way for a brand’s commercial success.  Hence this course addresses the need for pharma companies to equip their medical affairs departments with new competencies. The Expert: Chris Toller, a physician by education, built a career that has enabled him to work with medical affairs teams all over the world and in just about every therapy area. He has discovered what distinguishes a successful medical affairs executive from the average performer. Apart from being a creative strategic thinker, Chris is an excellent communicator and an inspirational presenter.Medical Affairs for Modern Pharma is the only available public training course delivered by Chris Toller on this topic.